2024财年毛利率较去年同期上升1.0个百分点达47.6%，主系部分大宗原材料及包装材料单位耗用成本下 降，抵消因渠道多元化带来的产品结构变动使得集团平均单位售价同比略有降低的影响。受益于毛利率 提升和整体营业费用(分销成本与行政费用合计，后文同)控管得宜，同时因2024财年融资成本的减少及 所得税费用率较2023财年同比降低，2024财年本公司权益持有人应占利润额同比成长8.6%达到43.356亿 人民币，权益持有人应占利润率较去年同期上升1.5个百分点达18.4%。集团将持续深化、强化组织的活 力和能动性，以提升对市场变化的快速反应能力，并进一步扩大市场份额。同时，积极开发新产品，拓 展终端覆盖范围，增强消费者的新鲜感与粘性。尽管当前部分大宗原物料成本有所上涨，但凭借多元化 的原材料使用策略，集团会尽力将成本波动的风险降至最低。 格隆汇6月24日丨中国旺旺(00151.HK)公布，截至2025年3月31日止年度，公司收益为人民币235.11亿 元，同比减少0.3%；毛利为人民币 111.89亿元，同比增长1.8%；营运利润为人民币58.37亿元，同比增 长4.1%。公司权益持有人应占利润为人民币43.36 ...

Fox Factory (FOXF) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Toby Merchant - Chief Legal Officer, Chief Compliance Officer & SecretaryMichael Dennison - CEO & DirectorDennis Schemm - President of AAG & CFOJames Duffy - Managing DirectorPeter Lukas - DirectorMichael Swartz - Director - Equity ResearchBret Jordan - Managing Director Conference Call Participants Anna Glaessgen - Senior Analyst, ConsumerScott Stember - Executive Director & Senior Research Analyst Operator Good afternoo ...

Financial Data and Key Metrics Changes - Total revenue increased approximately 17.2% year on year to $207.8 million, reflecting a 26.3% benefit from recent acquisitions, partially offset by an organic revenue decline of 8.1% [16][18] - Adjusted operating margin increased 280 basis points year on year to a record 19.4% [16] - Adjusted earnings per share increased 3.7% year on year to $1.95 [17] - Free cash flow for the third quarter was $3.5 million, down from $19.3 million a year ago, impacted by one-time transaction-related payments and longer customer credit terms [18] Business Line Data and Key Metrics Changes - **Electronics Segment**: Revenue increased 38.4% year on year to $111.3 million, with a 48.1% benefit from acquisitions, partially offset by an organic decline of 8.9% [19] - **Engraving Segment**: Revenue decreased 15.7% to $30.6 million, driven by an organic decline of 12.6% [21] - **Scientific Segment**: Revenue increased 8.1% to $18.3 million, due to a 16.1% benefit from recent acquisitions, partially offset by an organic decline of 8% [22] - **Engineering Technologies Segment**: Revenue increased 36.2% to $27.4 million, driven by a 26.3% benefit from recent acquisitions and organic growth of 9.9% [23] - **Specialty Solutions Segment**: Revenue decreased 13.9% year on year to $20.2 million, primarily due to general market softness [24] Market Data and Key Metrics Changes - Sales into fast growth markets increased to 29% of total company sales, primarily driven by electrical grid, commercialization of space, defense applications, and renewable energy [7][26] - Electronics organic bookings were up more than 10% year on year, with a book to bill ratio of 0.98, indicating stable markets [5][19] Company Strategy and Development Direction - The company plans to continue investing in new product development and applications across markets with growth potential, with 13 new products released year to date [26][28] - The company is expanding its footprint in Europe and the U.S. to support additional demand, with a greenfield site in Europe expected to be operational within six months [6][20] - The company anticipates achieving long-term targets of sales greater than $1.15 billion, adjusted operating margin greater than 23%, and ROIC greater than 15.5% by fiscal 2028 [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's agility and resilience to navigate through current economic challenges, emphasizing strong customer relationships and a disciplined approach to pricing and productivity actions [11][28] - The company expects slightly to moderately higher revenue and adjusted operating margin in the fiscal fourth quarter, driven by recent acquisitions and higher sales into fast growth end markets [9][21] Other Important Information - The company declared its 243rd consecutive cash dividend of $0.32 per share, representing a 6.7% increase year on year [25] - The company has a current liquidity of approximately $170 million and net debt of $470.4 million, with a leverage ratio of 2.8 [24][25] Q&A Session Summary Question: What is the impact of tariffs on the company's operations? - Approximately 6% of the cost of goods sold is due to imports from China, split across electronics, specialty, and scientific segments [32] - The company believes it can cover about 70% of the incremental tariff with price and productivity actions in the scientific segment, while other segments are expected to manage better [34][35] Question: What are the expectations for organic growth in fiscal 2026? - Management is optimistic about organic growth in electronics, with a robust order book and expected contributions from recent acquisitions [36][38] Question: What are the plans for new product releases in fiscal 2026? - The company plans to release a similar number of new products in fiscal 2026 as in fiscal 2025, with ongoing adoption expected from products released in 2025 [75] Question: How is the company managing its leverage and potential acquisitions? - The company aims to prioritize paying down debt while also focusing on organic growth initiatives, with a current leverage ratio of about 2.8 [56][58]

Federal Signal (FSS) Q1 2025 Earnings Call April 30, 2025 10:00 AM ET Company Participants Felix Boeschen - VP of Corporate Strategy & Investor RelationsIan Hudson - Senior VP & CFOJennifer Sherman - President & Chief Executive OfficerJacob Moore - Equity Research AssociateSam Karlov - Research Associate Conference Call Participants Tim Thein - Managing Director & Research AnalystChris Moore - Senior AnalystLinda Wiley - AnalystGregory Burns - Analyst Operator Greetings, and welcome to the Federal Signal Co ...

新产品、新产能、新市场有序拓展，筑牢自身发展基础1）新产品：截至24 年底，公司安全自毁留置 针、双头安全自锁胰岛素笔针头、动物疫苗连续计数注射器、低残留注射器等产品已完成研发并投入生 产；预充式导管冲洗器、营养喂食注射器、精密过滤盒等产品已处于产品试验及生产流程完善阶段。 2）新产能：截至24 年底，公司位于澄鹿路的二期厂房项目已部分完工，海外产能建设正持续推进。 3）新市场：截至24年底，公司多款产品已获得加拿大、沙特等国的产品注册证，新兴市场开拓工作有 序推进。我们看好公司通过新产品、新产能及新市场开发积极收获业绩增量并进一步提升整体抗风险能 力，夯实长期发展基础。 盈利预测与估值 综合考虑公司新产品、新市场开发对于收入增速的拉动及强化产品推广对于销售费用率的影响，我们调 整25-27 年归母净利至0.74/0.83/0.93 亿元（相比25/26 年前值调整-9%/-14%）。公司为注射穿刺器械领 域领军者，产品品类丰富且客户持续拓展，给予公司25 年34x PE （可比公司Wind 一致预期均值 32x），调整目标价至20.59 元（前值18.62 元，对应24 年33x PE）。 公司1Q25 收 ...

证券简称： 一致魔芋 证券代码： 839273 长阳经济开发区长阳大道 438 号 湖北一致魔芋生物科技股份有限公司 HUBEI YIZHI KONJAC BIOTECHNOLOGY CO.,LTD. 湖北一致魔芋生物科技股份有限公司招股说明书 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证 券交易所主要服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风 险高等特点，投资者面临较大的市场风险。投资者应充分了解北京证券交易所市场的 投资风险及本公司所披露的风险因素，审慎作出投资决定。 保荐机构（主承销商） 深圳市南山区粤海街道海珠社区滨海大道 3165 号五矿金融大厦 2401 湖北一致魔芋生物科技股份有限公司 招股说明书 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表 明其对注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不 表明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或 者保证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由 发行人自行负责；投资者自主判断发行人的投 ...